Total Payments
$134,915
2024 Payments
$1,235
Companies
36
Transactions
442
Payment Breakdown by Category
Research$121,860 (90.3%)
Food & Beverage$7,462 (5.5%)
Other$3,420 (2.5%)
Travel$2,174 (1.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $121,860 | 27 | 90.3% |
| Food and Beverage | $7,462 | 400 | 5.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,420 | 2 | 2.5% |
| Travel and Lodging | $2,174 | 13 | 1.6% |
Payments by Type
Research
$121,860
27 transactions
General
$13,055
415 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Arbor Pharmaceuticals, Inc. | $111,988 | 7 | $0 (2019) |
| Eli Lilly and Company | $6,917 | 3 | $0 (2021) |
| Ironshore Pharmaceuticals Inc. | $5,356 | 26 | $0 (2023) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,857 | 12 | $0 (2021) |
| Allergan, Inc. | $1,814 | 65 | $0 (2020) |
| Merck Sharp & Dohme LLC | $1,029 | 8 | $0 (2023) |
| ABBVIE INC. | $758.48 | 53 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $754.07 | 26 | $0 (2024) |
| Lundbeck LLC | $508.64 | 35 | $0 (2024) |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $372.91 | 14 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,235 | 47 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) ($372.91) |
| 2023 | $2,104 | 63 | Merck Sharp & Dohme LLC ($1,010) |
| 2022 | $853.30 | 52 | ABBVIE INC. ($169.11) |
| 2021 | $1,469 | 61 | Eli Lilly and Company ($676.59) |
| 2020 | $2,511 | 57 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($1,794) |
| 2019 | $118,231 | 73 | Arbor Pharmaceuticals, Inc. ($111,988) |
| 2018 | $2,219 | 42 | Eli Lilly and Company ($1,719) |
| 2017 | $6,294 | 47 | Eli Lilly and Company ($4,521) |
All Payment Transactions
442 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | In-kind items and services | $16.92 | General |
| Category: SCHIZOPHRENIA | ||||||
| 11/25/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $21.39 | General |
| Category: PSYCHIATRY | ||||||
| 11/20/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $18.92 | General |
| Category: PSYCHIATRY | ||||||
| 11/19/2024 | Neuronetics, Inc. | NEUROSTAR TMS THERAPY SYSTEM (Device) | Food and Beverage | Cash or cash equivalent | $29.01 | General |
| Category: NEUROSTAR TMS THERAPY SYSTEM | ||||||
| 11/13/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $18.86 | General |
| Category: PSYCHIATRY | ||||||
| 11/13/2024 | Tris Pharma Inc | Dyanavel XR (Drug) | Food and Beverage | In-kind items and services | $16.26 | General |
| Category: ADHD | ||||||
| 11/07/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $21.61 | General |
| Category: Psychology/Psychiatric | ||||||
| 10/31/2024 | UCB SA | — | Food and Beverage | In-kind items and services | $25.64 | General |
| 10/28/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $22.15 | General |
| Category: Psychology/Psychiatric | ||||||
| 10/23/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $13.12 | General |
| Category: PSYCHIATRY | ||||||
| 10/21/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $20.77 | General |
| Category: Neuroscience | ||||||
| 10/21/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | In-kind items and services | $16.15 | General |
| Category: SCHIZOPHRENIA | ||||||
| 09/19/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.19 | General |
| Category: NEUROSCIENCE | ||||||
| 09/17/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $19.99 | General |
| Category: PSYCHIATRY | ||||||
| 09/09/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $16.39 | General |
| 08/12/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $16.58 | General |
| Category: Psychology/Psychiatric | ||||||
| 08/01/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $18.61 | General |
| Category: PSYCHIATRY | ||||||
| 07/23/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $17.61 | General |
| Category: PSYCHIATRY | ||||||
| 07/22/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $16.70 | General |
| Category: PSYCHIATRY | ||||||
| 07/16/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $18.92 | General |
| Category: Psychology/Psychiatric | ||||||
| 06/26/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $25.69 | General |
| Category: PSYCHIATRY | ||||||
| 06/20/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $16.54 | General |
| Category: NEUROSCIENCE | ||||||
| 06/17/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $20.03 | General |
| Category: Psychology/Psychiatric | ||||||
| 06/12/2024 | Axsome Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $122.28 | General |
| 06/12/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $17.66 | General |
| Category: PSYCHIATRY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Adult Attention Deficit Hyperactivity Disorder ADHD Study With Amphetamine Sulfate | Arbor Pharmaceuticals, Inc. | $111,988 | 7 |
| MULTIPLE-DOSE, DOSE-ESCALATION STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF LY3303560 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMERS DISEASE OR MILD TO MODERATE ALZHEIMERS DISEASE | Eli Lilly and Company | $6,241 | 2 |
| BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,794 | 10 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $676.59 | 1 |
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $616.00 | 2 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | Allergan Inc. | $356.00 | 1 |
| M15-566 | AbbVie, Inc. | $124.18 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER | Allergan Inc. | $3.70 | 2 |
About Dr. Jeffrey Apter, MD
Dr. Jeffrey Apter, MD is a Psychiatry healthcare provider based in Princeton, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/31/2007. The National Provider Identifier (NPI) number assigned to this provider is 1568509495.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jeffrey Apter, MD has received a total of $134,915 in payments from pharmaceutical and medical device companies, with $1,235 received in 2024. These payments were reported across 442 transactions from 36 companies. The most common payment nature is "" ($121,860).
Ad
Practice Information
- Specialty Psychiatry
- Location Princeton, NJ
- Active Since 01/31/2007
- Last Updated 07/08/2007
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1568509495
Products in Payments
- AR19 (Drug) $111,988
- Jornay PM 20mg capsules (Bottle of 100) (Drug) $5,316
- REXULTI (Drug) $2,926
- VRAYLAR (Drug) $1,284
- CAPLYTA (Drug) $600.24
- LATUDA (Drug) $344.87
- Dyanavel XR (Drug) $344.51
- TRINTELLIX (Drug) $338.86
- SPRAVATO (Drug) $281.48
- Auvelity (Drug) $201.08
- Trintellix (Drug) $194.00
- AUSTEDO (Drug) $128.42
- HETLIOZ (Drug) $123.65
- AMYVID (Drug) $104.14
- AZSTARYS (Drug) $102.37
- LYBALVI (Drug) $101.30
- NAMZARIC (Drug) $94.01
- QELBREE (Drug) $87.18
- Azstarys (Drug) $85.89
- FANAPT (Drug) $75.91
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Princeton
Dr. Jeffrey Mattes, Md, MD
Psychiatry — Payments: $15,411
Psychiatry $15,411
Sanjay Varma, M.d, M.D
Psychiatry — Payments: $7,382
Psychiatry $7,382
Dr. Alina Vrinceanu-Hamm, M.d, M.D
Psychiatry — Payments: $5,935
Psychiatry $5,935
Dr. Saranga Bhalla, D.o, D.O
Psychiatry — Payments: $4,993
Psychiatry $4,993
Sonja Gray, M.d, M.D
Psychiatry — Payments: $2,480
Psychiatry $2,480
Dr. Steven Levine, M.d, M.D
Psychiatry — Payments: $2,143
Psychiatry $2,143